| 000 | 01447 a2200385 4500 | ||
|---|---|---|---|
| 005 | 20250515070626.0 | ||
| 264 | 0 | _c20070621 | |
| 008 | 200706s 0 0 eng d | ||
| 022 | _a1537-6591 | ||
| 024 | 7 |
_a10.1086/518386 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLin, Chih-Lin | |
| 245 | 0 | 0 |
_aTo genotype or not to genotype: toward an optimal tailoring of treatment of chronic hepatitis B. _h[electronic resource] |
| 260 |
_bClinical infectious diseases : an official publication of the Infectious Diseases Society of America _cJun 2007 |
||
| 300 |
_a1665-6 p. _bdigital |
||
| 500 | _aPublication Type: Letter | ||
| 650 | 0 | 4 |
_aAntiviral Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aDNA, Viral _xblood |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGenotype |
| 650 | 0 | 4 |
_aHepatitis B e Antigens _xblood |
| 650 | 0 | 4 |
_aHepatitis B virus _xclassification |
| 650 | 0 | 4 |
_aHepatitis B, Chronic _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInterferon alpha-2 |
| 650 | 0 | 4 |
_aInterferon-alpha _xtherapeutic use |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aPolyethylene Glycols _xtherapeutic use |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aRecombinant Proteins |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aKao, Jia-Horng | |
| 773 | 0 |
_tClinical infectious diseases : an official publication of the Infectious Diseases Society of America _gvol. 44 _gno. 12 _gp. 1665-6 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1086/518386 _zAvailable from publisher's website |
| 999 |
_c17060288 _d17060288 |
||